Cargando…

Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action

Aromatase inhibitors (AIs) reduce breast cancer recurrence and prolong survival, but up to 30% of patients exhibit recurrence. Using a genome-wide association study of patients entered on MA.27, a phase III randomized trial of anastrozole versus exemestane, we identified a single nucleotide polymorp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cairns, Junmei, Ingle, James N., Dudenkov, Tanda M., Kalari, Krishna R., Carlson, Erin E., Na, Jie, Buzdar, Aman U., Robson, Mark E., Ellis, Matthew J., Goss, Paul E., Shepherd, Lois E., Goodnature, Barbara, Goetz, Matthew P., Weinshilboum, Richard M., Li, Hu, Bari, Mehrab Ghanat, Wang, Liewei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455128/ https://www.ncbi.nlm.nih.gov/pubmed/32701512 http://dx.doi.org/10.1172/jci.insight.137571

Ejemplares similares

Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early‐Stage Breast Cancer
por: Cairns, Junmei, et al.
Publicado: (2021)

Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome‐Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2
por: Dudenkov, Tanda M., et al.
Publicado: (2019)

The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1
por: Cairns, Junmei, et al.
Publicado: (2019)

Anastrozole (Arimidex ™) – an aromatase inhibitor for the adjuvant setting?
por: Buzdar, A U
Publicado: (2001)

Pharmacogenomic Discovery to Function and Mechanism: Breast Cancer as a Case Study
por: Wang, Liewei, et al.
Publicado: (2017)

Pharmacogenomics in Practice
por: Wang, Liewei, et al.
Publicado: (2019)

Metformin Pharmacogenomics: Biomarkers to Mechanisms
por: Wang, Liewei, et al.
Publicado: (2014)

Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes
por: Liu, Duan, et al.
Publicado: (2017)

Gemcitabine and Arabinosylcytosin Pharmacogenomics: Genome-Wide Association and Drug Response Biomarkers
por: Li, Liang, et al.
Publicado: (2009)

SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ERα-positive breast cancer through regulation of BRCA1
por: Cairns, Junmei, et al.
Publicado: (2017)

Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy
por: GHIMENTI, CHIARA, et al.
Publicado: (2013)

Anastrozole-Induced Dermatitis: Report of a Woman with an Anastrozole-Associated Dermatosis and a Review of Aromatase Inhibitor-Related Cutaneous Adverse Events
por: Kim, Yoo Jung, et al.
Publicado: (2020)

Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole – of clinical importance?
por: Geisler, J
Publicado: (2011)

A Polymorphism at the 3′-UTR Region of the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor, Anastrozole, in Metastatic Breast Carcinoma
por: Liu, Lei, et al.
Publicado: (2013)

Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression
por: Liu, Mohan, et al.
Publicado: (2012)

Knowledge-guided gene prioritization reveals new insights into the mechanisms of chemoresistance
por: Emad, Amin, et al.
Publicado: (2017)

CDC25B partners with PP2A to induce AMPK activation and tumor suppression in triple negative breast cancer
por: Cairns, Junmei, et al.
Publicado: (2020)

Model-based unsupervised learning informs metformin-induced cell-migration inhibition through an AMPK-independent mechanism in breast cancer
por: Athreya, Arjun P., et al.
Publicado: (2017)

Leveraging an Electronic Health Record-Linked Biorepository to Generate a Metformin Pharmacogenomics Hypothesis
por: Breitenstein, Matthew K., et al.
Publicado: (2015)

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
por: Jayaraman, Swaathi, et al.
Publicado: (2020)

Rethinking the combination treatment of fulvestrant and anastrozole for metastatic breast cancer: an integrated reanalysis of aromatase–estrogen receptor axis
por: Huang, Xing
Publicado: (2019)

Machine Learning-Assisted Network Inference Approach to Identify a New Class of Genes that Coordinate the Functionality of Cancer Networks
por: Ghanat Bari, Mehrab, et al.
Publicado: (2017)

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
por: Geisler, J., et al.
Publicado: (1996)

Early response index: a statistic to discover potential early stage disease biomarkers
por: Salekin, Sirajul, et al.
Publicado: (2017)

Regulostat Inferelator: a novel network biology platform to uncover molecular devices that predetermine cellular response phenotypes
por: Ung, Choong Yong, et al.
Publicado: (2019)

Segmental Erythema Multiforme-Like Drug Eruption by Aromatase Inhibitor Anastrozole – First Case Report and another Example of an Immunocompromised District
por: Wollina, Uwe, et al.
Publicado: (2018)

SLCO1B1 genetic variation and hormone therapy in menopausal women
por: Moyer, Ann M., et al.
Publicado: (2018)

Considerations for automated machine learning in clinical metabolic profiling: Altered homocysteine plasma concentration associated with metformin exposure
por: Orlenko, Alena, et al.
Publicado: (2018)

Impact of Pharmacogenomic Information on Values of Care and Quality of Life Associated with Codeine and Tramadol-Related Adverse Drug Events
por: Zhu, Ye, et al.
Publicado: (2021)

A network-based phenotype mapping approach to identify genes that modulate drug response phenotypes
por: Cairns, Junmei, et al.
Publicado: (2016)

Testis- specific Y-encoded- like protein 1 and cholesterol metabolism: Regulation of CYP1B1 expression through Wnt signaling
por: Zhu, Xiujuan, et al.
Publicado: (2022)

Pharmacogenomics of endocrine therapy in breast cancer
por: Ingle, James N
Publicado: (2013)

A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none?
por: Zhu, Ye, et al.
Publicado: (2020)

Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases
por: Zhu, Ye, et al.
Publicado: (2019)

Are patients willing to incur out of pocket costs for pharmacogenomic testing?
por: Bielinski, Suzette J., et al.
Publicado: (2016)

Response of Mouse Breast Cancer Cells to Anastrozole, Tamoxifen, and the Combination
por: Xanthopoulos, J. M., et al.
Publicado: (2005)

Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer
por: Ingle, James N
Publicado: (2008)

Effects of psoralen on the pharmacokinetics of anastrozole in rats
por: Zhang, Yuzhu, et al.
Publicado: (2018)

SLCO1B1: Application and Limitations of Deep Mutational Scanning for Genomic Missense Variant Function
por: Zhang, Lingxin, et al.
Publicado: (2021)

ZNF423 modulates the AMP-activated protein kinase pathway and metformin response in a single nucleotide polymorphisms, estrogen and selective estrogen receptor modulator dependent fashion
por: Qin, Sisi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ep5h8883bf1lolngjqpf5ivjgt